|
Neoplasm Metastasis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Conversely, PSR activation of cancer cells plays an important role in their survival, proliferation and metastasis.
|
31172440 |
2019 |
|
Periodontal Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Effects of smoking and genotype on the PSR index of periodontal disease in adults aged 18-49.
|
23066400 |
2012 |
|
Iron deficiency
|
0.010 |
Biomarker
|
disease |
BEFREE |
Effects similar to iron deficiency were generated by siRNA knockdown of either splicing factor U2AF(65) or Fe(II)- and 2-oxoglutarate-dependent dioxygenase Jumonji domain-containing protein 6 (Jmjd6), which interacts with U2AF(65) by lysyl-hydroxylation.
|
23787363 |
2013 |
|
Choriocarcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Exposure of primary isolated trophoblast cells, human villous explants, and JEG3 choriocarcinoma cells to low oxygen (3%) and sodium nitroprusside (inducer of oxidative stress) also resulted in elevated JMJD6 levels, which was abrogated by HIF1A knockdown.
|
26037477 |
2015 |
|
Neoplasm Metastasis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Further, since high levels of HOTAIR promote metastasis and death, blocking JMJD6 may be useful in preventing such events.
|
29229759 |
2018 |
|
mathematical ability
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals.
|
30038396 |
2018 |
|
Mammary Tumorigenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Given the pleiotropic pro-tumorigenic activities of JMJD6, it may be useful as a prognostic factor and a therapeutic target for Myc-driven mammary tumorigenesis.
|
27081402 |
2016 |
|
Diabetes, Autoimmune
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Here we report that TEC-specific deletion of Jmjd6 exacerbates development of autoimmune diabetes in a mouse model, which express both ovalbumin (OVA) under the control of the rat insulin gene promoter and OT-I T cell receptor specific for OVA peptide bound to major histocompatibility complex class I K<sup>b</sup> molecules.
|
28546003 |
2017 |
|
Malignant neoplasm of breast
|
0.350 |
Biomarker
|
disease |
BEFREE |
However, the precise role of JMJD6 in breast cancer development remains unclear.
|
30185813 |
2019 |
|
Breast Carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
However, the precise role of JMJD6 in breast cancer development remains unclear.
|
30185813 |
2019 |
|
Malignant Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
However, there are no studies reporting the expression of JMJD6 in ovarian cancer, and no JMJD6 inhibitors have been developed and applied to targeted cancer therapy research.
|
31637004 |
2019 |
|
Primary malignant neoplasm
|
0.080 |
Biomarker
|
group |
BEFREE |
However, there are no studies reporting the expression of JMJD6 in ovarian cancer, and no JMJD6 inhibitors have been developed and applied to targeted cancer therapy research.
|
31637004 |
2019 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical staining revealed that high JMJD6 expression was closely correlated with tumor size (P = 0.005), pathological grade (P = 0.003), pT status (P = 0.012), pN status (P = 0.003), and pleural invasion (P < 0.001).
|
23595221 |
2013 |
|
Tumor Cell Invasion
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Immunohistochemical staining revealed that high JMJD6 expression was closely correlated with tumor size (P = 0.005), pathological grade (P = 0.003), pT status (P = 0.012), pN status (P = 0.003), and pleural invasion (P < 0.001).
|
23595221 |
2013 |
|
Malignant neoplasm of breast
|
0.350 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry, siRNA-mediated silencing, and forced overexpression of JMJD6 in cell-based assays elucidated molecular mechanisms of JMJD6 action in breast cancer progression and shed light on the clinical breast cancer subtypes relevant to JMJD6 action.
|
22621393 |
2012 |
|
Breast Carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry, siRNA-mediated silencing, and forced overexpression of JMJD6 in cell-based assays elucidated molecular mechanisms of JMJD6 action in breast cancer progression and shed light on the clinical breast cancer subtypes relevant to JMJD6 action.
|
22621393 |
2012 |
|
Carcinogenesis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Importantly, knockdown of JMJD6 represses p53-dependent colon cell proliferation and tumorigenesis in vivo, and significantly, the expression of JMJD6 is markedly up-regulated in various types of human cancer especially in colon cancer, and high nuclear JMJD6 protein is strongly correlated with aggressive clinical behaviors of colon adenocarcinomas.
|
24667498 |
2014 |
|
Adenocarcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Importantly, knockdown of JMJD6 represses p53-dependent colon cell proliferation and tumorigenesis in vivo, and significantly, the expression of JMJD6 is markedly up-regulated in various types of human cancer especially in colon cancer, and high nuclear JMJD6 protein is strongly correlated with aggressive clinical behaviors of colon adenocarcinomas.
|
24667498 |
2014 |
|
Malignant Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Importantly, knockdown of JMJD6 represses p53-dependent colon cell proliferation and tumorigenesis in vivo, and significantly, the expression of JMJD6 is markedly up-regulated in various types of human cancer especially in colon cancer, and high nuclear JMJD6 protein is strongly correlated with aggressive clinical behaviors of colon adenocarcinomas.
|
24667498 |
2014 |
|
Primary malignant neoplasm
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Importantly, knockdown of JMJD6 represses p53-dependent colon cell proliferation and tumorigenesis in vivo, and significantly, the expression of JMJD6 is markedly up-regulated in various types of human cancer especially in colon cancer, and high nuclear JMJD6 protein is strongly correlated with aggressive clinical behaviors of colon adenocarcinomas.
|
24667498 |
2014 |
|
Oestrogen receptor positive breast cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Importantly, we demonstrate that co-expression of high levels of JMJD6 and Myc is associated with poor prognosis for human ER+ breast cancer patients.
|
27081402 |
2016 |
|
estrogen receptor-negative breast cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Importantly, we demonstrate that co-expression of high levels of JMJD6 and Myc is associated with poor prognosis for human ER+ breast cancer patients.
|
27081402 |
2016 |
|
Nevus comedonicus
|
0.010 |
Biomarker
|
disease |
BEFREE |
In addition, expression levels of its downstream effectors IL‑1β, TNF‑α and VEGF were attenuated by intrathecal treatment with LV‑JMJD6, compared with those in the NS‑ and NC‑treated CCI rats.
|
29620141 |
2018 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
In addition, knockdown of JMJD6 in invasive cell lines, such as MDA-MB231, decreased motility and invasion, whereas overexpression in MCF-7 cells slightly promoted motility but did not confer invasive growth.
|
22621393 |
2012 |
|
Transient Ischemic Attack
|
0.010 |
Biomarker
|
disease |
BEFREE |
In all, 153 patients met the preliminary diagnostic criteria for PSR: transient worsening of residual poststroke focal neurologic deficits or transient recurrence of prior stroke-related focal deficits, admission magnetic resonance imaging showing a chronic stroke but no acute infarct or hemorrhage, no evidence of transient ischemic attack or seizure, no acute lesion on diffusion-weighted imaging, and no clinical or electroencephalographic evidence of seizure around the time of the event.
|
28783808 |
2017 |